Another study shows that higher expression of IL21R in patients with primary HER2+ breast cancer is associated with positive effects of trastuzumab with respect to DFS, suggesting a possible role of IL21R as predictive marker for anti-HER232. The gene discussed is ERBB2; the disease is breast carcinoma.